Gustavo Viani: Osimertinib post-CRT as the standard of care in unresectable stage III EGFR mutated NSCLC

Gustavo Viani, Associate Professor in the Department of Medical Imaging, Hematology, and Oncology at Hospital das Clínicas, posted the following on LinkedIn:

“LAURA Trial supports osimertinib post-CRT as the standard of care in unresectable stage III EGFRm NSCLC.

Objective:

Investigate the CNS efficacy and time to distant metastasis (TTDM) of osimertinib in  with unresectable stage III EGFR-mutated NSCLC without progression after chemoradiotherapy.

Methods:

216 patients were randomized (2:1) to receive osimertinib (80 mg daily) or placebo

1. endpoint: progression-free survival (PFS) by blinded independent central review (BICR)
2. endpoints: CNS PFS and TTDM.

Results:

• Median CNS PFS was not reached with osimertinib vs. 14.9 months with placebo.
• CNS progression at 12 months: 9% with osimertinib vs. 36% with placebo.
• TTDM showed significant increases with osimertinib (HR: 0.21), with a lower cumulative incidence of distant metastases at 12 months (11% vs. 37% placebo).”

Gustavo Viani, MD is an Associate Professor in the Department of Medical Imaging, Hematology, and Oncology at Hospital das Clínicas, Faculty of Medicine of Ribeirão Preto, University of São Paulo (FMRP-USP). Dr. Viani’s research focuses on radiation oncology, with expertise in brachytherapy, stereotactic radiosurgery, dose fractionation, radiation tolerance, and overall oncology practices.